An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.
about
Enhancers: five essential questionsGenetic variations in colorectal cancer risk and clinical outcomePleiotropy in complex traits: challenges and strategiesIDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulationGenome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese populationA genome-wide association study of female sexual dysfunctionHaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variantsMYC on the path to cancerA genome-wide survey for SNPs altering microRNA seed sites identifies functional candidates in GWAS.Chromatin states reveal functional associations for globally defined transcription start sites in four human cell lines.On the identification of potential regulatory variants within genome wide association candidate SNP sets.MYC Deregulation in Primary Human Cancers.Methods for cancer epigenome analysis.A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression.Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP.Expression and mutation analyses implicate ARHGAP29 as the etiologic gene for the cleft lip with or without cleft palate locus identified by genome-wide association on chromosome 1p22.A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestryPolymorphisms on 8q24 are associated with lung cancer risk and survival in Han ChineseExpression QTL-based analyses reveal candidate causal genes and loci across five tumor types.Common genetic variants in miR-1206 (8q24.2) and miR-612 (11q13.3) affect biogenesis of mature miRNA formsCohesin is required for activation of MYC by estradiol.Differences in enhancer activity in mouse and zebrafish reporter assays are often associated with changes in gene expression.Enhancer variants: evaluating functions in common disease.TRACER: a resource to study the regulatory architecture of the mouse genomeUltra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetranceAssociation between polymorphism rs6983267 and gastric cancer risk in Chinese populationChromosome 8q24-Associated Cancers and MYC.Structural variation-associated expression changes are paralleled by chromatin architecture modifications.Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisAlterations in TCF7L2 expression define its role as a key regulator of glucose metabolism.Genetic susceptibility to bladder cancer risk and outcome.Identification and computational analysis of gene regulatory elements.Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease.Mapping of disease-associated variants in admixed populations.Identification of cis-regulatory sequence variations in individual genome sequences.Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detectionNetworks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.Association of three 8q24 polymorphisms with prostate cancer susceptibility: evidence from a meta-analysis with 50,854 subjects.Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.Principles for the post-GWAS functional characterization of cancer risk loci
P2860
Q22121999-C93C740A-2327-4B1A-8DE8-3CB21CDB7776Q27002944-20E5BF5B-BA78-4AB0-9DF4-786077F54AF2Q28390545-634B8D9B-BFCB-472B-8186-2A7717B9CE18Q28396617-30886A7F-EC07-4E01-9370-AC8894CA20E4Q28943340-CEBF18B9-3008-4A57-84D1-476F27007324Q28943500-B9886BF6-AD47-4B97-89FD-B6770521310DQ29614906-6EC58942-D12F-43D9-9825-FAC1A1B74AABQ29619979-4B98A20C-5C5A-48CD-90DF-FF41E0AE8955Q31034509-9A500649-BE43-42A0-95B1-54EA94361D9DQ31154613-C7C9D58D-AB80-4EFE-BC07-25797E67F562Q33789149-B314138C-A0EB-4D4B-97C9-312B378C3DA0Q33836755-BEB6A195-EFEB-4032-857F-18023BD6C5B9Q33874869-A66CC805-52D1-49D0-BBB1-B7544DD44C1FQ33981307-80780825-CB9C-4040-B18D-33A5CB761377Q34238083-C7964F1F-99E2-4AD6-B27C-01FFAFBDC0F6Q34301707-069F4403-9331-4668-AD56-EC6A0F87D972Q34353049-87EDFD32-EC1B-4F9A-8BC1-4E26DBB0A3AEQ34359258-4BF9DCE5-C70F-4797-94BC-8124A37285EDQ34430369-75FE8869-4057-4D91-B4D4-D4F500939ABEQ34450872-4752C4E9-56E7-4D04-82EC-C97A82B7E480Q34474156-243CD85C-004D-4142-A132-87CCA970EB7CQ34518186-9C71C582-2433-414E-A135-3FDDAC69122FQ34624842-F8C46637-9651-4E57-AC0A-A9E2BF7134CEQ34645234-B903339F-53F3-4484-AB7F-E812E9DCAF55Q34729785-10B198C9-AC69-4243-BF1F-4B1565F21F5BQ34772076-2C56941F-CCAB-4CA0-B26F-D74FB4E2A8E3Q34972340-CF56F015-F1D8-4AD1-AC4B-375DD9AD847EQ35050556-91939C91-639E-4C79-B2EE-26CAB39783E3Q35185164-82533302-3B16-440D-A426-A2B88F712E94Q35195941-91A4B152-1358-4E7A-B0B2-80F6968AC973Q35212792-1C28A1A8-12E7-4B81-AC6E-ED4DB5A1B5E7Q35538633-2D38D9CE-8462-4E82-8E54-1836BF0E4EA9Q35557622-59D52027-F471-4AA0-A7E3-9F1899EF420EQ35561144-A0AACF79-42B1-4369-B1AC-B0FF3AE622BBQ35617343-DAC1E92B-C3BD-4A2F-92D4-A990EBA648DFQ35661317-862DD608-84F5-4279-BE32-66CCA61AAF33Q35695044-9A4AC0E3-66E0-4141-B5A9-9C1AFB4A74E7Q35837515-621CA868-99B6-428A-AE9B-13EF02973704Q35863853-13ACD0F1-E369-4504-A814-CE28F3CD7C55Q35887461-67D33323-9D99-4AF8-B852-A6FB2A4FCF52
P2860
An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@ast
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@en
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@nl
type
label
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@ast
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@en
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@nl
prefLabel
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@ast
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@en
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@nl
P2093
P2860
P356
P1433
P1476
An 8q24 gene desert variant as ...... vo activity to a MYC enhancer.
@en
P2093
Marcelo A Nobrega
Nora F Wasserman
P2860
P304
P356
10.1101/GR.105361.110
P577
2010-07-13T00:00:00Z